• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Overweight body habitus is associated with higher rates of relapse in children with acute lymphoblastic leukemia

bySiwen LiuandAlex Chan
August 7, 2025
in Chronic Disease, Oncology, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Among children with acute lymphoblastic leukemia, overweight or obesity at >2 time points (longer duration) was associated with higher rates of relapse and lower overall survival compared to those with overweight or obesity at <1 time point. 

Evidence Rating Level: 2 (Good)

Study Rundown: Some studies have found that among children with acute lymphoblastic leukemia (ALL), the presence of overweight or obesity at diagnosis has been linked to increased risk of treatment-related toxic effects (TRTEs) and mortality. However, other studies suggest that it may be the duration of exposure to overweight or obesity that contributes to the increased risk of adverse outcomes. This study thus investigated the association between the duration of overweight or obesity with TRTEs, end of induction (EOI), minimal residual disease (MRD), relapse, and survival among children undergoing treatment for ALL. This prospective cohort study included 794 children and adolescents aged 1 to 18 years with newly diagnosed ALL. Body mass index (BMI) z scores were compared from diagnosis to end of treatment (EOT). The prevalence of overweight or obesity increased from 29.5% (234 of 793) at diagnosis to 48.4% (346 of 715) by EOT. Change in BMI classification from diagnosis to EOI was not associated with high MRD at EOI. Children with overweight or obesity at two or more time points experienced lower overall survival (OS), higher relapse rate, and lower event-free survival (EFS), compared with children with overweight or obesity at one or no time point. When examining hazard ratios, children with overweight or obesity at two or more time points had an increased risk of death and relapse compared to children with overweight or obesity at one or no time point. Overall, a longer duration of overweight or obesity was linked to lower OS and EFS, as well as higher rates of relapse. 

Click to read the study in BMC Medicine

Relevant reading: Body mass index during maintenance therapy and relapse risk in children with acute lymphoblastic leukemia: A Children’s Oncology Group report

In-Depth [Prospective cohort study]: This study included 794 children and adolescents aged 1 to 18 years with newly diagnosed ALL who were registered on a Dana Farber Cancer Institute ALL Consortium protocol from May 31, 2005, to December 15, 2011. The duration of overweight or obesity was defined as having overweight or obesity at two or more time points and compared with having overweight or obesity at one or no time points. In total, 794 patients were included in the analysis (mean age [range] = 6.7 (1.0-17.9) years, male [%] = 441 [55.5%]). Over a mean (SD) follow-up time of 8.2 (3.6) years from diagnosis, the prevalence of overweight or obesity increased from 29.5% (234 of 793) at diagnosis to 48.4% (346 of 715) by EOT. Change in BMI classification from diagnosis to EOI was not associated with high MRD at EOI. Children with overweight or obesity at two or more time points experienced lower OS, higher relapse, and lower event-free survival, compared with children with overweight or obesity at one or no time point (3-year OS, 93.8% vs 98.0%, 3-year relapse rate, 10.5% vs 5.8%, 3-year event-free survival, 89.0% vs 93.7%; P < .05 for all). Furthermore, children with overweight or obesity at two or more time points had an increased risk of death (hazard ratio [HR], 3.49; 95% CI, 1.28-9.51; P = .01) and relapse (HR, 1.92; 95% CI, 1.07-3.46; P = .03) compared to children with overweight or obesity at one or no time point. Overall, longer duration of overweight or obesity was associated with lower OS and EFS, as well as higher rates of relapse, highlighting the need for targeted interventions to address overweight or obesity during treatment of children with ALL. One limitation of this study is that BMI z scores may underestimate adiposity in children with ALL, potentially leading to misclassification within the cohort. Additionally, some variables that affect overweight and obesity in children were not available, such as stage of pubertal status, physical activity, and food security. Future studies should address these limitations in large cohorts.

RELATED REPORTS

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial

Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen 

Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

Tags: ALLchronic diseaseleukemiaoncologypediatrics
Previous Post

#VisualAbstract: Perioperative Durvalumab increased Survival in Gastric and Gastroesopha-geal Junction Cancer

Next Post

Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease

RelatedReports

Parents of children with autism report greater difficulty accessing health care
Chronic Disease

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial

December 22, 2025
2 Minute Medicine Rewind March 4, 2019
Chronic Disease

Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen 

December 10, 2025
Lisinopril and carvedilol reduce cardiotoxicity in breast cancer patients receiving trastuzumab and anthracyclines
Cardiology

Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines

December 8, 2025
Severity of emphysema on pulmonary CT may predict lung cancer location
Chronic Disease

Age-Based Screening for Lung Cancer Surveillance in the US

November 26, 2025
Next Post
Unenhanced magnetic resonance imaging highly sensitive and specific for acute appendicitis

Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease

Rectal indomethacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients

mFOLFIRINOX may have a limited role in pancreatic cancer in Phase II/III trial

#VisualAbstract: Inavolisib Increased Overall Survival in PIK3CA-Mutated Advanced Breast Cancer

#VisualAbstract: Inavolisib Increased Overall Survival in PIK3CA-Mutated Advanced Breast Cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry
  • Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial
  • Weekly islatravir plus lenacapavir maintains HIV virologic suppression
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.